Moreover, we show that the PIK3CA mutational status did not influence the response to the PI3K inhibitor MEN1611 in NSCLC, suggesting the possibility of exploring combination therapy in patients with an EGFR mutation and constitutive activation of the PI3K/AKT/mTOR pathway. Here, EGFR is linked to non-small cell lung carcinoma.